Form 4: Schrodinger Officer Sells Shares for Tax Liability

Schrodinger's EVP, Chief Scientific Officer, Robert Lorne Abel, sold 1,300 shares of common stock to cover tax obligations from RSU vesting.

Summary

• Robert Lorne Abel, EVP, Chief Scientific Officer, Platform at Schrodinger, Inc. (SDGR), sold 1,300 shares of common stock.
• The transaction occurred on March 4, 2026, at a price of $12.81 per share.
• The sale was executed under a Rule 10b5-1 trading plan adopted on August 25, 2025.
• The purpose of the sale was to satisfy withholding tax liability incurred upon the vesting of restricted stock units (RSUs).
• This was a non-discretionary trade by the reporting person.
• Following the transaction, Robert Lorne Abel beneficially owns 55,897 shares, which includes 49,824 unvested RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine, non-discretionary transaction to cover tax obligations from RSU vesting, not an indication of management's sentiment on the company's future.

Positives

• The sale was non-discretionary, executed under a pre-arranged Rule 10b5-1 plan, indicating a structured approach to managing equity compensation and tax obligations rather than a discretionary move based on market sentiment.

Management Comments

• This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2025, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units ('RSUs'). The sale does not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that insider sales to cover tax liabilities upon RSU vesting are common practice across industries, particularly in technology and biotech firms like Schrodinger, where equity compensation is a significant component of executive pay. Such sales are generally not interpreted as a negative signal regarding the company's future prospects, unlike discretionary sales.

Comparison to Industry Standards

• Sales to cover tax obligations from RSU vesting are standard practice for executives across publicly traded companies, including peers in the biotech and software sectors such as Moderna (MRNA) or Palantir (PLTR), where equity compensation is prevalent.
• The use of a Rule 10b5-1 plan aligns with best practices for insider trading compliance, providing an affirmative defense against insider trading allegations by pre-scheduling trades.

Stakeholder Impact

• Shareholders: The sale of 1,300 shares by an officer is a minor dilution event but is generally not seen as a negative signal due to its non-discretionary nature for tax purposes.

Key Dates

Recommendation

This Form 4 filing reports a routine, non-discretionary sale of shares by an officer to cover tax liabilities associated with RSU vesting. Such transactions, executed under a Rule 10b5-1 plan, do not typically reflect a change in management's outlook on the company's fundamentals or future prospects. Therefore, it provides no new information that would warrant a change in investment recommendation; a "hold" stance is appropriate as investors should look to broader financial reports and strategic updates for investment decisions.

Keywords

Schrodinger, SDGR, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Restricted Stock Units, RSU, Tax Liability, Officer Transaction, Robert Lorne Abel